Abstract
Conventional treatment of autoimmune hemolytic anemia (AIHA) comprises corticosteroids and splenectomy and/or other immunosuppressive drugs for refractory/relapsed patients. Monoclonal antibodies (MoAbs) rituximab and alemtuzumab have gained widespread acceptance in the management of B-cell malignancies. More recently, they have been used to treat a number of autoantibody-mediated diseases, such as both idiopathic and secondary AIHA, with encouraging results. Herein we report an overview of the medical literature on the use of MoAbs to treat AIHA. The therapeutic mechanism of action of rituximab in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus is currently a subject of considerable investigation. We have proposed that cell-associated IgG immune complexes, generated by the binding of rituximab to CD20 on B cells, may serve as decoys that attract FcγR-expressing effector cells and downregulate effector cell pathogenic action, thus reducing inflammation and tissue destruction in these diseases. We briefly review evidence that suggests that this immune complex decoy hypothesis plays a role in the therapeutic action of rituximab in AIHA, and we propose new measurements that should allow for a more complete evaluation of the importance of this mechanism in AIHA.
Keywords: Autoimmune hemolytic anemia, monoclonal antibodies, therapy, rituximab, alemtuzumab
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Volume: 8 Issue: 1
Author(s): Giovanni D'Arena, Ronald P. Taylor, Nicola Cascavilla and Margaret A. Lindorfer
Affiliation:
Keywords: Autoimmune hemolytic anemia, monoclonal antibodies, therapy, rituximab, alemtuzumab
Abstract: Conventional treatment of autoimmune hemolytic anemia (AIHA) comprises corticosteroids and splenectomy and/or other immunosuppressive drugs for refractory/relapsed patients. Monoclonal antibodies (MoAbs) rituximab and alemtuzumab have gained widespread acceptance in the management of B-cell malignancies. More recently, they have been used to treat a number of autoantibody-mediated diseases, such as both idiopathic and secondary AIHA, with encouraging results. Herein we report an overview of the medical literature on the use of MoAbs to treat AIHA. The therapeutic mechanism of action of rituximab in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus is currently a subject of considerable investigation. We have proposed that cell-associated IgG immune complexes, generated by the binding of rituximab to CD20 on B cells, may serve as decoys that attract FcγR-expressing effector cells and downregulate effector cell pathogenic action, thus reducing inflammation and tissue destruction in these diseases. We briefly review evidence that suggests that this immune complex decoy hypothesis plays a role in the therapeutic action of rituximab in AIHA, and we propose new measurements that should allow for a more complete evaluation of the importance of this mechanism in AIHA.
Export Options
About this article
Cite this article as:
D'Arena Giovanni, Taylor P. Ronald, Cascavilla Nicola and Lindorfer A. Margaret, Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/187153008783928370
DOI https://dx.doi.org/10.2174/187153008783928370 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endogenous Repair System of Oxidative Damage of DNA
Current Chemical Biology Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Gold and Silver Nanoparticles in Bioassay, Cell Visualization and Therapy
Current Clinical Pharmacology Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets A Proteomics Study of the Subacute Toxicity of Rat Brain after Long- Term Exposure of <i>Gelsemium elegans</i>
Current Molecular Pharmacology Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Human Complex Trait Genetics: Lifting the Lid of the Genomics Toolbox - from Pathways to Prediction
Current Genomics Iontophoretic Mediated Intraarticular Delivery of Deformable Liposomes of Diclofenac Sodium
Current Drug Delivery Properties and Therapeutic Potential of Transient Receptor Potential Channels with Putative Roles in Adversity: Focus on TRPC5, TRPM2 and TRPA1
Current Drug Targets Current Screens Based on the AlphaScreen™ Technology for Deciphering Cell Signalling Pathways
Current Genomics Lung Defence Mechanisms and Their Potential Role in the Prevention of Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery The Genetic Basis of Graves Disease
Current Genomics S100A8/A9 as a Pro-inflammatory Cytokine in Obstructive Airway Disease Via the Multi-Ligand Receptor, RAGE
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adipokines as Novel Links between Obesity and Insulin Resistance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Chemical Inhibition of Matrix Metalloproteinases for Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Anti-Inflammatory Drugs and the Heart Special Thematic)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept
Current Rheumatology Reviews Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine